slide 1

Back to the List of the Granted Patents                                                Click here to download AP2150 PDF

(11)    Patent No :    AP 2150    (73) Applicant(s)       
(21)    Application No :    AP/P/2006/003640    TIBOTEC PHARMACEUTICALS LTD., Little Island , Co Cork,       
            Ireland       
                   
(22)    Filing Date :    20.12.2004           
(24)    Date of Grant &    04.09.2010           
                   
(45)    Publication :

(30)    Priority Data                    (72) Inventors   
    (33) Country    (31) Number    (32) Date    BONFANTI Jean-François, France   
    EP            03104810.1    18.12.2003    ANDRIES Koenraad Jozef Lodewijk, Belgium   
    US            60/567,182        30.04.2004       
                            FORTIN Jérôme, Michel, Claude, United States of   
    EP            04105312.5    26.10.2004       
                        America       
    et al                                   
                                et al       
                                       
                                (74) Representative   
(84)    Designated State                   
                           
    BW    GM    GH    KE    LS    MW    MZ   NA   SL    HONEY & BLANCKENBERG   
    SD    SZ    T Z    UG    ZM    ZW               
                   
(51)    International    Classification    A61K 31/4184 (2006.01)    C07D401/06 (2006.01)   
                            C07D413/14 (2006.01)       

(54)    Title

Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication

(57)    Abstract

The present invention concerns morpholinyl containing benzimidazoles having inhibitory activity on the replication of the respiratory syncytial virus and having the formula (I), a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein G is a direct bond or optionally m substituted C1-10alkanediyl; R1 is Ar1 or a monocyclic or

bicyclic heterocycle Q is R7, pyrrolidinyl substituted with R7, piperidinyl substituted with R7 or homopiperidinyl substituted with R7; one of R2a7and R3a is selected from halo, optionally mono- or polysubstituted C1-6alkyl, optionally mono- or polysubstituted C2-6alkenyl, nilro, hydroxy, Ar2, N(R4aR4), N(R4aR4)sulfonyl, N(R4aR4b)carbonyl, C1 -6alkyloxy, Ar2oxy, Ar2C1-6alkyloxy, carboxyl, C1-6alkyloxycarbonyl, or -C(=Z)Ar2; and the other one of R2a and R3a is hydrogen; in case R2a is different from hydrogen then R2bis hydrogen, C1 -6alkyl or halogen and R3bis hydrogen; in case R3a is different from hydrogen then R3b is hydrogen, C1 -6alkyl or halogen and R2b is hydrogen. It further concerns the preparation thereof and compositions

(56)    Documents Cited :    JANSEENS F ET AL    WO 01/00615    WO 01/00612    WO 01/00611

Newsletter

Join our newsletter for CIPIT news through subscriptions!

SEND

Social Media

    

Contact Us

TEL : (254) 703 034 612